Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for the Treatment of Advanced Prostate Cancer; Changchun GeneScience Pharmaceutical will Commercialize in China

Foresee Pharmaceuticals says China’s National Medical Products Administration (NMPA) has approved CAMCEVI® 42 mg for adult patients with advanced prostate cancer. The company, listed on the Taipei Exchange (TPEx: 6576), received the notification through its licensing partner, Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci). CAMCEVI® 42 mg is a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate. Foresee CEO Dr. Ben Chien said GenSci’s launch in China will support growth of the CAMCEVI® franchise globally. Foresee notes CAMCEVI® is exclusively licensed to GenSci in China for advanced prostate cancer and also for central precocious puberty and premenopausal breast cancer. GenSci has also filed an sNDA in May 2026 for leuprolide mesylate for premenopausal breast cancer, now under review.